- Home
- HSBC vs GILD Comparison
HSBC vs GILD Comparison
Compare HSBC & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HSBC | GILD |
|---|---|---|
| Founded | 1865 | 1987 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 336.4B | 165.0B |
| IPO Year | 2014 | 2003 |
Fundamental Metrics
Financial Performance| Metric | HSBC | GILD |
|---|---|---|
| Price | $104.09 | $146.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 18 |
| Target Price | N/A | ★ $148.39 |
| AVG Volume (30 Days) | 1.1M | ★ 6.4M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.18% | 2.55% |
| EPS Growth | N/A | ★ 1684.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,689,000,000.00 |
| Revenue This Year | $14.95 | $4.68 |
| Revenue Next Year | $3.66 | $6.04 |
| P/E Ratio | $94.79 | ★ N/A |
| Revenue Growth | N/A | ★ 9.98 |
| 52 Week Low | $63.55 | $108.46 |
| 52 Week High | $107.92 | $157.29 |
Technical Indicators
Market Signals| Indicator | HSBC | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 55.98 | 67.10 |
| Support Level | $101.73 | $142.93 |
| Resistance Level | $104.66 | $149.38 |
| Average True Range (ATR) | 1.11 | 3.96 |
| MACD | -0.35 | 1.15 |
| Stochastic Oscillator | 78.16 | 85.86 |
Price Performance
Historical ComparisonAbout HSBC HSBC Holdings plc.
Established in 1865 in Hong Kong, London-based HSBC is one of the largest banks in the world, with assets of USD 3 trillion and over 40 million customers worldwide. It operates in more than 50 countries with over 200,000 full-time staff. Hong Kong and the United Kingdom are its two largest markets. The bank offers retail, commercial and institutional banking, global banking and markets, wealth management, and private banking.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).